We are live on ! Find out more
MLTX icon

MoonLake Immunotherapeutics
MLTX

43 hedge funds and large institutions have $843M invested in MoonLake Immunotherapeutics in 2023 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 11 increasing their positions, 6 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

113% more capital invested

Capital invested by funds: $396M → $843M (+$447M)

91% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 11

83% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 6

30% more funds holding

Funds holding: 33 → 43 (+10)

3.85% more ownership

Funds ownership: 96.84% → 100.69% (+3.8%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

Holders
43
Holders Change
+10
Holders Change %
+30.3%
% of All Funds
0.69%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
21
Increased
11
Reduced
6
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$28.1M
2
CAM
Cormorant Asset Management
Massachusetts
+$13.9M
3
Federated Hermes
Federated Hermes
Pennsylvania
+$13.5M
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$4.87M
5
JP Morgan Chase
JP Morgan Chase
New York
+$4.34M

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$10.5M
2
TCM
TCG Crossover Management
California
-$10.5M
3
GPP
Great Point Partners
Connecticut
-$6.12M
4
B
Braidwell
Connecticut
-$4M
5
TCM
Tekla Capital Management
Massachusetts
-$3.15M
Name Holding Trade Value Shares
Change 		Change in
Stake
Manulife (Manufacturers Life Insurance)
26
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$1.04M +$816K +48,550 New
5VM
27
5AM Venture Management
California
$831K +$653K +38,856 New
SSA
28
Schonfeld Strategic Advisors
New York
$796K +$625K +37,200 New
Millennium Management
29
Millennium Management
New York
$750K +$590K +35,071 New
Morgan Stanley
30
Morgan Stanley
New York
$696K +$86.7K +5,154 +19%
Point72 Asset Management
31
Point72 Asset Management
Connecticut
$636K +$500K +29,748 New
Jane Street
32
Jane Street
New York
$557K +$438K +26,034 New
VCIM
33
Velan Capital Investment Management
Georgia
$501K +$393K +23,400 New
Renaissance Technologies
34
Renaissance Technologies
New York
$486K +$186K +11,091 +96%
Geode Capital Management
35
Geode Capital Management
Massachusetts
$366K +$95.1K +5,658 +49%
SFG
36
SVB Financial Group
Texas
$346K – – –
BHCM
37
Boulder Hill Capital Management
New York
$310K +$244K +14,500 New
Ensign Peak Advisors
38
Ensign Peak Advisors
Utah
$248K +$195K +11,575 New
Bank of America
39
Bank of America
North Carolina
$220K +$40K +2,380 +30%
UBS Group
40
UBS Group
Switzerland
$170K -$1.1M -65,428 -89%
DWA
41
Dorsey Wright & Associates
California
$21.4K +$16.8K +1,000 New
Royal Bank of Canada
42
Royal Bank of Canada
Ontario, Canada
$14K +$9.75K +580 +763%
Osaic Holdings
43
Osaic Holdings
Arizona
$1.62K +$1.28K +76 New
TCM
44
TCG Crossover Management
California
– -$10.5M -1,000,000 Closed
B
45
Braidwell
Connecticut
– -$4M -381,120 Closed
TCM
46
Tekla Capital Management
Massachusetts
– -$3.15M -300,000 Closed
TCM
47
Tang Capital Management
California
– -$2.58M -245,714 Closed
ACP
48
Acuta Capital Partners
California
– -$982K -93,500 Closed
Barclays
49
Barclays
United Kingdom
– -$587K -55,952 Closed
CCMU
50
Cheyne Capital Management (UK)
United Kingdom
– -$337K -32,129 Closed
1
2
3

MLTX Hedge Fund Activity: Q1 2023 in Review

43 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in MoonLake Immunotherapeutics (MLTX) for Q1 2023, worth a combined $843M — up 113% from $396M a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new MLTX positions and 11 closed out — a net gain of 10 holders — while 11 added to existing stakes and 6 trimmed.

The largest buyer was Adage Capital Partners, opening a new position worth an estimated $28.1M. The largest seller was BlackRock, cutting an estimated $10.5M.

  • 43 institutional investors held MoonLake Immunotherapeutics (MLTX) as of Q1 2023, up from 33 in Q4 2022.
  • Funds reported $843M of MoonLake Immunotherapeutics stock for Q1 2023, up 113% quarter-over-quarter.
  • 21 funds opened new MoonLake Immunotherapeutics positions in Q1 2023 and 11 closed out, a net change of +10 holders.
  • The largest MoonLake Immunotherapeutics buyer in Q1 2023 was Adage Capital Partners, an estimated $28.1M added.
  • The largest MoonLake Immunotherapeutics seller in Q1 2023 was BlackRock, an estimated $10.5M sold.

Based on aggregated 13F filings for Q1 2023.